Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.37 CAD | -7.50% | +13.85% | -13.95% |
Valuation
Fiscal Period: September | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 26.97 | 58.8 | 21.89 | 19.94 | 22.21 | - | - |
Enterprise Value (EV) 1 | 26.97 | 69.12 | 40.9 | 46.06 | 67.61 | 63.81 | 22.21 |
P/E ratio | 700 x | 39.3 x | - | - | - | - | - |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 1.3 x | 0.88 x | 0.27 x | 0.22 x | 0.13 x | 0.12 x | 0.12 x |
EV / Revenue | 1.3 x | 1.04 x | 0.51 x | 0.51 x | 0.39 x | 0.36 x | 0.12 x |
EV / EBITDA | - | 11.7 x | 7.1 x | 5.6 x | 5.21 x | 4.02 x | 1.17 x |
EV / FCF | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 38,529 | 53,453 | 56,138 | 55,392 | 55,514 | - | - |
Reference price 2 | 0.7000 | 1.100 | 0.3900 | 0.3600 | 0.4000 | 0.4000 | 0.4000 |
Announcement Date | 12/18/20 | 12/21/21 | 12/22/22 | 12/12/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 20.74 | 66.63 | 80.51 | 90.39 | 172.2 | 179.4 | 179.6 |
EBITDA 1 | - | 5.902 | 5.76 | 8.227 | 12.98 | 15.89 | 19.03 |
EBIT | - | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - |
Net income | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - |
EPS | 0.001000 | 0.0280 | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 12/18/20 | 12/21/21 | 12/22/22 | 12/12/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: September | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 18.42 | 17.58 | 22.42 | 22.09 | 21.58 | 21.8 | 23.61 | 36.97 | 46.28 | 46.9 |
EBITDA 1 | 1.486 | 0.4668 | 1.586 | 2.222 | 1.504 | 1.936 | 2.715 | 2.622 | 2.576 | 3.2 |
EBIT | - | - | - | - | - | - | - | 1.175 | - | - |
Operating Margin | - | - | - | - | - | - | - | 3.18% | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | 0.203 | - | - |
Net income | - | - | - | - | - | - | - | -0.231 | - | - |
Net margin | - | - | - | - | - | - | - | -0.62% | - | - |
EPS | - | - | - | - | - | - | - | -0.004000 | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/23/22 | 5/18/22 | 8/24/22 | 12/22/22 | 2/22/23 | 5/29/23 | 8/24/23 | 2/26/24 | 5/23/24 | - |
Balance Sheet Analysis
Fiscal Period: September | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | 10.3 | 19 | 26.1 | 45.4 | 41.6 | - |
Net Cash position 1 | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | 1.749 x | 3.299 x | 3.175 x | 3.498 x | 2.618 x | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 12/18/20 | 12/21/21 | 12/22/22 | 12/12/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.95% | 16.3M | |
-25.41% | 197B | |
-0.45% | 57.39B | |
-23.97% | 55.93B | |
-13.32% | 45.1B | |
-10.40% | 36.57B | |
-1.28% | 35.55B | |
-13.33% | 27.48B | |
+103.26% | 27.21B | |
-2.20% | 20.85B |
- Stock Market
- Equities
- PHA Stock
- Financials Premier Health of America Inc.